Literature DB >> 15165002

Effects of Graves' ophthalmopathy on quality of life.

W M Wiersinga1, M F Prummel, C B Terwee.   

Abstract

General health-related quality of life is markedly impaired in patients with Graves' ophthalmopathy (GO), and even worse than in patients with other chronic conditions like diabetes, emphysema or heart failure. A disease-specific quality-of-life questionnaire for GO has been developed, the so-called GO-QOL, consisting of two subscales: one for visual functioning (8 questions referring to limitations due to decreased visual acuity and/or diplopia) and one for appearance (8 questions referring to limitations in psychosocial functioning due to changes in appearance). The GO-QOL was found to be a valid and reliable instrument. A minimal clinically important difference (MCID) in the GO-QOL score was derived from data obtained before and after specific eye treatments. Based on the patient's opinions, changes of > or = 6 points (minor surgery) or > or = 10 points (surgical decompression, immunosuppression) are recommended as MCID. It is concluded that the GO-QOL is an useful instrument for measuring changes over time in visual functioning and appearance of GO patients. The GO-QOL is available in six languages, and can be used as a separate outcome measure in clinical studies.

Entities:  

Mesh:

Year:  2004        PMID: 15165002     DOI: 10.1007/BF03345275

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

1.  Should quality-of-life needs influence resource allocation?

Authors:  P Fayers; K Bjordal
Journal:  Lancet       Date:  2001-03-31       Impact factor: 79.321

2.  Classification of eye changes of Graves' disease.

Authors: 
Journal:  Thyroid       Date:  1992       Impact factor: 6.568

3.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

4.  Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations.

Authors:  N K Aaronson; M Muller; P D Cohen; M L Essink-Bot; M Fekkes; R Sanderman; M A Sprangers; A te Velde; E Verrips
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

5.  Users' guides to the medical literature. XII. How to use articles about health-related quality of life. Evidence-Based Medicine Working Group.

Authors:  G H Guyatt; C D Naylor; E Juniper; D K Heyland; R Jaeschke; D J Cook
Journal:  JAMA       Date:  1997-04-16       Impact factor: 56.272

6.  The relationship of patient satisfaction with care and clinical outcomes.

Authors:  R L Kane; M Maciejewski; M Finch
Journal:  Med Care       Date:  1997-07       Impact factor: 2.983

7.  Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument.

Authors:  M N Gerding; C B Terwee; F W Dekker; L Koornneef; M F Prummel; W M Wiersinga
Journal:  Thyroid       Date:  1997-12       Impact factor: 6.568

8.  Which chronic conditions are associated with better or poorer quality of life?

Authors:  M A Sprangers; E B de Regt; F Andries; H M van Agt; R V Bijl; J B de Boer; M Foets; N Hoeymans; A E Jacobs; G I Kempen; H S Miedema; M A Tijhuis; H C de Haes
Journal:  J Clin Epidemiol       Date:  2000-09       Impact factor: 6.437

9.  Graves ophthalmopathy. Results of transantral orbital decompression performed primarily for cosmetic indications.

Authors:  V Fatourechi; J A Garrity; G B Bartley; E J Bergstralh; L W DeSanto; C A Gorman
Journal:  Ophthalmology       Date:  1994-05       Impact factor: 12.079

10.  Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study.

Authors:  A L Stewart; S Greenfield; R D Hays; K Wells; W H Rogers; S D Berry; E A McGlynn; J E Ware
Journal:  JAMA       Date:  1989-08-18       Impact factor: 56.272

View more
  18 in total

Review 1.  Pharmacological treatments for thyroid eye disease.

Authors:  Sara P Modjtahedi; Bobeck S Modjtahedi; Ahmad M Mansury; Dinesh Selva; Raymond S Douglas; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Graves' ophthalmopathy: search for shared autoantigen(s) continues.

Authors:  L Bartalena
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

Review 3.  An update on medical management of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; M L Tanda; E Piantanida; A Lai; M Marinò; A Pinchera
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

4.  Currently available somatostatin analogs are not good for Graves' orbitopathy.

Authors:  M L Tanda; L Bartalena
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

5.  Immunotherapy for Graves' orbitopathy: easy enthusiasm, but let's keep trying.

Authors:  L Bartalena; M L Tanda
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

Review 6.  Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?

Authors:  L Bartalena; C Marcocci; A Lai; M L Tanda
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

7.  Measuring quality of life in oculoplastic patients.

Authors:  Edward Ridyard; Clare Inkster
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

8.  Randomized controlled trial of rituximab in patients with Graves' orbitopathy.

Authors:  Marius N Stan; James A Garrity; Barbara G Carranza Leon; Thapa Prabin; Elizabeth A Bradley; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2014-10-24       Impact factor: 5.958

9.  Incidence and clinical presentation of moderate to severe graves' orbitopathy in a Danish population before and after iodine fortification of salt.

Authors:  Peter Laurberg; Dalia C Berman; Inge Bülow Pedersen; Stig Andersen; Allan Carlé
Journal:  J Clin Endocrinol Metab       Date:  2012-04-19       Impact factor: 5.958

Review 10.  Thyroid eye disease: towards an evidence base for treatment in the 21st century.

Authors:  Erin F Gillespie; Terry J Smith; Raymond S Douglas
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.